Old Articles: <Older 8761-8770 Newer> |
|
Chemistry World January 22, 2014 Mico Tatalovic |
Croatia's vaccines manufacturer left hanging as it enters administration The government has pledged to find a solution and to keep production of key products in Croatia as it looks for strategic partners to invest in restructuring the ailing institute. |
Pharmaceutical Executive January 21, 2014 William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Pharmaceutical Executive January 21, 2014 Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Pharmaceutical Executive January 21, 2014 Ben Comer |
Biosimilars or Bust Will biosimimilars make much of an impact on drug cost? |
Pharmaceutical Executive January 21, 2014 Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
Pharmaceutical Executive January 21, 2014 William Looney |
For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist. |
Pharmaceutical Executive January 1, 2014 Stan Bernard |
The 7 Habits of Highly Effective Competitions Lessons to win in a shifting market dynamic |
Pharmaceutical Executive January 1, 2014 Jill Wechsler |
Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing |
Pharmaceutical Executive December 1, 2013 William Looney |
Executive Profile:United BioSource's Patrick Lindsay For Patrick Lindsay, providing decision support across the full product life cycle is no stretch; it's today's fact of life |
Pharmaceutical Executive December 1, 2013 Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
<Older 8761-8770 Newer> Return to current articles. |